Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ependymoma | 16 | 2023 | 326 | 3.990 |
Why?
|
Medulloblastoma | 22 | 2022 | 679 | 3.530 |
Why?
|
Cerebellar Neoplasms | 18 | 2022 | 588 | 3.470 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 14 | 2022 | 497 | 3.380 |
Why?
|
Brain Neoplasms | 37 | 2024 | 9101 | 2.250 |
Why?
|
Photons | 16 | 2022 | 588 | 2.230 |
Why?
|
Protons | 24 | 2024 | 1097 | 2.130 |
Why?
|
Skull Base Neoplasms | 4 | 2024 | 280 | 2.080 |
Why?
|
Radiotherapy Dosage | 45 | 2024 | 2911 | 2.050 |
Why?
|
Chordoma | 6 | 2024 | 349 | 2.030 |
Why?
|
Chondrosarcoma | 4 | 2024 | 305 | 1.850 |
Why?
|
Lymphokines | 19 | 2001 | 924 | 1.770 |
Why?
|
Germinoma | 8 | 2022 | 132 | 1.740 |
Why?
|
Radiotherapy, Conformal | 12 | 2018 | 545 | 1.600 |
Why?
|
Spinal Cord Neoplasms | 5 | 2023 | 263 | 1.580 |
Why?
|
Central Nervous System Neoplasms | 8 | 2022 | 926 | 1.540 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 25 | 2024 | 1667 | 1.520 |
Why?
|
Histamine Release | 17 | 2001 | 134 | 1.510 |
Why?
|
Radiotherapy, Intensity-Modulated | 13 | 2023 | 794 | 1.470 |
Why?
|
Breast Neoplasms | 41 | 2024 | 21162 | 1.440 |
Why?
|
Thoracic Wall | 6 | 2019 | 203 | 1.370 |
Why?
|
Relative Biological Effectiveness | 14 | 2021 | 313 | 1.320 |
Why?
|
Cranial Irradiation | 8 | 2022 | 392 | 1.150 |
Why?
|
Linear Energy Transfer | 7 | 2021 | 154 | 1.130 |
Why?
|
Pineal Gland | 4 | 2022 | 158 | 1.040 |
Why?
|
Basophils | 15 | 2001 | 407 | 0.990 |
Why?
|
Spinal Neoplasms | 6 | 2025 | 714 | 0.970 |
Why?
|
Neoplasms, Second Primary | 4 | 2019 | 1061 | 0.890 |
Why?
|
Immunoglobulin E | 15 | 2001 | 1495 | 0.880 |
Why?
|
Radiation Injuries | 11 | 2022 | 1194 | 0.860 |
Why?
|
Sturge-Weber Syndrome | 2 | 2022 | 89 | 0.840 |
Why?
|
Choroid Neoplasms | 2 | 2022 | 177 | 0.840 |
Why?
|
Testicular Neoplasms | 5 | 2022 | 805 | 0.830 |
Why?
|
Child | 82 | 2024 | 80668 | 0.830 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2019 | 543 | 0.820 |
Why?
|
Organs at Risk | 13 | 2023 | 365 | 0.780 |
Why?
|
Brain Stem | 6 | 2022 | 858 | 0.770 |
Why?
|
Child, Preschool | 57 | 2024 | 42577 | 0.760 |
Why?
|
Olfaction Disorders | 1 | 2024 | 225 | 0.750 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2024 | 9404 | 0.730 |
Why?
|
Hemangioma | 3 | 2022 | 727 | 0.710 |
Why?
|
Rehabilitation | 1 | 2021 | 129 | 0.700 |
Why?
|
Radiation Oncology | 2 | 2024 | 571 | 0.680 |
Why?
|
Lymphatic Metastasis | 6 | 2016 | 2901 | 0.670 |
Why?
|
Infratentorial Neoplasms | 5 | 2018 | 99 | 0.600 |
Why?
|
Mastectomy | 10 | 2019 | 1861 | 0.600 |
Why?
|
Supratentorial Neoplasms | 3 | 2013 | 156 | 0.590 |
Why?
|
Lymphatic Irradiation | 5 | 2024 | 115 | 0.580 |
Why?
|
Adolescent | 56 | 2024 | 88904 | 0.570 |
Why?
|
Humans | 186 | 2025 | 766766 | 0.560 |
Why?
|
Professional-Patient Relations | 1 | 2022 | 724 | 0.560 |
Why?
|
Hemangiosarcoma | 1 | 2019 | 214 | 0.550 |
Why?
|
Retinoblastoma | 3 | 2014 | 321 | 0.540 |
Why?
|
Hematologic Diseases | 1 | 2020 | 502 | 0.540 |
Why?
|
Radiotherapy | 5 | 2019 | 1497 | 0.540 |
Why?
|
Teratoma | 3 | 2022 | 405 | 0.530 |
Why?
|
Community Health Services | 1 | 2021 | 659 | 0.520 |
Why?
|
Young Adult | 44 | 2024 | 59939 | 0.520 |
Why?
|
Gynecomastia | 1 | 2016 | 88 | 0.520 |
Why?
|
Radiotherapy, High-Energy | 2 | 2007 | 228 | 0.510 |
Why?
|
Telemedicine | 2 | 2024 | 3111 | 0.510 |
Why?
|
Glioma | 7 | 2020 | 3498 | 0.510 |
Why?
|
Carotid Stenosis | 1 | 2023 | 858 | 0.500 |
Why?
|
Pituitary Neoplasms | 2 | 2021 | 1324 | 0.490 |
Why?
|
Scattering, Radiation | 1 | 2017 | 483 | 0.480 |
Why?
|
Infant | 31 | 2024 | 36461 | 0.480 |
Why?
|
Radiodermatitis | 3 | 2014 | 61 | 0.470 |
Why?
|
Lymph Nodes | 4 | 2019 | 3468 | 0.460 |
Why?
|
Breast | 7 | 2021 | 1971 | 0.450 |
Why?
|
Quality-Adjusted Life Years | 3 | 2016 | 1740 | 0.440 |
Why?
|
Female | 103 | 2024 | 396520 | 0.440 |
Why?
|
Pituitary Gland, Posterior | 1 | 2013 | 42 | 0.430 |
Why?
|
Spine | 2 | 2019 | 1134 | 0.430 |
Why?
|
Delayed Diagnosis | 2 | 2016 | 454 | 0.430 |
Why?
|
Monte Carlo Method | 8 | 2020 | 1250 | 0.430 |
Why?
|
Sarcoma | 1 | 2024 | 1802 | 0.410 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2013 | 136 | 0.400 |
Why?
|
Rhabdoid Tumor | 2 | 2017 | 211 | 0.390 |
Why?
|
Spinal Cord | 2 | 2021 | 1811 | 0.390 |
Why?
|
Mammaplasty | 4 | 2019 | 1268 | 0.380 |
Why?
|
Automobile Driving | 1 | 2017 | 442 | 0.380 |
Why?
|
Combined Modality Therapy | 15 | 2025 | 8540 | 0.380 |
Why?
|
Vomiting | 4 | 2024 | 652 | 0.380 |
Why?
|
Treatment Outcome | 36 | 2024 | 65273 | 0.370 |
Why?
|
Retrospective Studies | 33 | 2024 | 81635 | 0.370 |
Why?
|
Hippocampus | 4 | 2022 | 3776 | 0.360 |
Why?
|
Male | 74 | 2024 | 364142 | 0.360 |
Why?
|
Radiometry | 6 | 2018 | 812 | 0.360 |
Why?
|
Hypogonadism | 1 | 2016 | 802 | 0.350 |
Why?
|
Head and Neck Neoplasms | 2 | 2023 | 2929 | 0.350 |
Why?
|
Neuroblastoma | 2 | 2024 | 1266 | 0.340 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2014 | 594 | 0.340 |
Why?
|
Rhabdomyosarcoma | 4 | 2014 | 358 | 0.340 |
Why?
|
Cost Savings | 1 | 2015 | 902 | 0.330 |
Why?
|
Nausea | 2 | 2024 | 681 | 0.330 |
Why?
|
Tumor Burden | 8 | 2021 | 1900 | 0.330 |
Why?
|
Craniopharyngioma | 3 | 2021 | 279 | 0.330 |
Why?
|
Neoplasms | 9 | 2024 | 22350 | 0.320 |
Why?
|
Radiotherapy, Adjuvant | 10 | 2021 | 1787 | 0.320 |
Why?
|
Mastectomy, Segmental | 7 | 2015 | 974 | 0.310 |
Why?
|
Treatment Failure | 6 | 2022 | 2659 | 0.310 |
Why?
|
Central Nervous System | 3 | 2022 | 1345 | 0.300 |
Why?
|
Moyamoya Disease | 2 | 2022 | 274 | 0.300 |
Why?
|
Dose-Response Relationship, Radiation | 6 | 2022 | 877 | 0.290 |
Why?
|
Sacrum | 3 | 2024 | 273 | 0.290 |
Why?
|
Radiation Dosage | 5 | 2024 | 1957 | 0.270 |
Why?
|
Breast Implants | 3 | 2019 | 414 | 0.270 |
Why?
|
Follow-Up Studies | 20 | 2023 | 39309 | 0.270 |
Why?
|
Immobilization | 1 | 2007 | 227 | 0.260 |
Why?
|
Recombinant Proteins | 11 | 2005 | 6507 | 0.260 |
Why?
|
Interleukin-4 | 4 | 1997 | 1155 | 0.260 |
Why?
|
Disease-Free Survival | 10 | 2022 | 6850 | 0.250 |
Why?
|
Gastroenteritis | 2 | 2019 | 233 | 0.250 |
Why?
|
Adult | 45 | 2024 | 223307 | 0.240 |
Why?
|
Cost-Benefit Analysis | 6 | 2021 | 5536 | 0.240 |
Why?
|
Prospective Studies | 20 | 2024 | 54871 | 0.240 |
Why?
|
Antibodies, Anti-Idiotypic | 6 | 1999 | 347 | 0.240 |
Why?
|
Heart | 3 | 2017 | 4425 | 0.230 |
Why?
|
Fetal Proteins | 1 | 2024 | 100 | 0.220 |
Why?
|
Stroke | 2 | 2023 | 9741 | 0.220 |
Why?
|
Omentum | 1 | 2024 | 168 | 0.210 |
Why?
|
Surgical Flaps | 2 | 2024 | 1680 | 0.210 |
Why?
|
Mastectomy, Modified Radical | 3 | 2015 | 62 | 0.210 |
Why?
|
Fatigue | 3 | 2024 | 1555 | 0.210 |
Why?
|
Radiography | 5 | 2015 | 6968 | 0.200 |
Why?
|
Retinal Neoplasms | 2 | 2014 | 151 | 0.190 |
Why?
|
Models, Economic | 3 | 2015 | 719 | 0.190 |
Why?
|
Granular Cell Tumor | 1 | 2022 | 48 | 0.190 |
Why?
|
Postoperative Care | 3 | 2018 | 1480 | 0.190 |
Why?
|
Magnetic Resonance Imaging | 10 | 2022 | 36567 | 0.190 |
Why?
|
Carboplatin | 2 | 2022 | 789 | 0.190 |
Why?
|
Fibrosarcoma | 1 | 2023 | 313 | 0.180 |
Why?
|
Interleukin-8 | 2 | 2001 | 702 | 0.180 |
Why?
|
Skull Base | 1 | 2023 | 294 | 0.180 |
Why?
|
Molecular Mimicry | 1 | 2001 | 212 | 0.180 |
Why?
|
Vincristine | 2 | 2020 | 1039 | 0.170 |
Why?
|
Evidence-Based Medicine | 2 | 2012 | 3692 | 0.170 |
Why?
|
Grief | 1 | 2022 | 256 | 0.170 |
Why?
|
Hypersensitivity, Immediate | 2 | 2001 | 348 | 0.170 |
Why?
|
Program Evaluation | 2 | 2021 | 2504 | 0.170 |
Why?
|
Orbital Neoplasms | 1 | 2022 | 223 | 0.170 |
Why?
|
Blood Cell Count | 1 | 2020 | 405 | 0.170 |
Why?
|
Quality of Life | 8 | 2024 | 13476 | 0.170 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2001 | 415 | 0.170 |
Why?
|
Radiobiology | 1 | 2020 | 90 | 0.160 |
Why?
|
Peer Review | 1 | 2021 | 218 | 0.160 |
Why?
|
Age Factors | 9 | 2021 | 18397 | 0.160 |
Why?
|
Vaccines | 2 | 2017 | 842 | 0.160 |
Why?
|
Pediatrics | 4 | 2020 | 3614 | 0.160 |
Why?
|
Eosinophils | 2 | 2001 | 952 | 0.160 |
Why?
|
Cognition | 6 | 2021 | 7057 | 0.160 |
Why?
|
Tattooing | 1 | 2019 | 57 | 0.160 |
Why?
|
Rib Fractures | 1 | 2020 | 124 | 0.160 |
Why?
|
Retinal Pigments | 1 | 1998 | 84 | 0.150 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2022 | 2143 | 0.150 |
Why?
|
Lymphopenia | 1 | 2021 | 299 | 0.150 |
Why?
|
Aged | 22 | 2024 | 171343 | 0.150 |
Why?
|
Middle Aged | 31 | 2024 | 223257 | 0.150 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 1999 | 192 | 0.150 |
Why?
|
Skull | 1 | 2023 | 819 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 11872 | 0.150 |
Why?
|
Patient Positioning | 2 | 2018 | 332 | 0.150 |
Why?
|
Pituitary Gland | 2 | 2018 | 635 | 0.150 |
Why?
|
Intelligence | 3 | 2018 | 925 | 0.150 |
Why?
|
Nanoparticles | 1 | 2009 | 1966 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 6512 | 0.140 |
Why?
|
Growth Disorders | 1 | 2022 | 634 | 0.140 |
Why?
|
Wechsler Scales | 1 | 2018 | 256 | 0.140 |
Why?
|
Dark Adaptation | 1 | 1998 | 224 | 0.140 |
Why?
|
Feasibility Studies | 4 | 2019 | 5306 | 0.140 |
Why?
|
Growth Plate | 2 | 2017 | 275 | 0.140 |
Why?
|
Independent Living | 1 | 2021 | 584 | 0.140 |
Why?
|
Chemokine CCL2 | 2 | 1996 | 604 | 0.140 |
Why?
|
Cohort Studies | 12 | 2022 | 41710 | 0.140 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2020 | 616 | 0.140 |
Why?
|
Consensus | 3 | 2022 | 3208 | 0.140 |
Why?
|
Rhabdomyosarcoma, Embryonal | 2 | 2015 | 99 | 0.140 |
Why?
|
Prognosis | 12 | 2023 | 29948 | 0.130 |
Why?
|
Contrast Sensitivity | 1 | 1998 | 253 | 0.130 |
Why?
|
Time Factors | 9 | 2021 | 40149 | 0.130 |
Why?
|
Cost Allocation | 1 | 2016 | 48 | 0.130 |
Why?
|
Practice Guidelines as Topic | 3 | 2018 | 7431 | 0.130 |
Why?
|
Survivors | 4 | 2020 | 2379 | 0.130 |
Why?
|
Diabetes Insipidus | 1 | 2016 | 144 | 0.130 |
Why?
|
Paraplegia | 1 | 2016 | 161 | 0.130 |
Why?
|
Vaccination | 2 | 2019 | 3434 | 0.130 |
Why?
|
Meningeal Neoplasms | 3 | 2015 | 1255 | 0.130 |
Why?
|
Bone Neoplasms | 2 | 2023 | 2561 | 0.130 |
Why?
|
Models, Econometric | 1 | 2016 | 216 | 0.120 |
Why?
|
Testis | 2 | 2016 | 786 | 0.120 |
Why?
|
Forecasting | 1 | 2024 | 2936 | 0.120 |
Why?
|
Endocrine System Diseases | 2 | 2018 | 247 | 0.120 |
Why?
|
alpha-Fetoproteins | 2 | 2013 | 229 | 0.120 |
Why?
|
Endocrine System | 1 | 2015 | 112 | 0.120 |
Why?
|
Interleukin-13 | 1 | 1997 | 391 | 0.120 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 588 | 0.120 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2015 | 58 | 0.120 |
Why?
|
Massachusetts | 3 | 2024 | 8891 | 0.120 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2020 | 447 | 0.120 |
Why?
|
Cold Temperature | 1 | 1998 | 794 | 0.120 |
Why?
|
Antineoplastic Agents | 5 | 2016 | 13643 | 0.110 |
Why?
|
Lectins | 1 | 1996 | 490 | 0.110 |
Why?
|
Alberta | 3 | 2019 | 67 | 0.110 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 505 | 0.110 |
Why?
|
Astrocytoma | 1 | 2018 | 773 | 0.110 |
Why?
|
Self Care | 1 | 2019 | 800 | 0.110 |
Why?
|
Disability Evaluation | 1 | 2021 | 1827 | 0.110 |
Why?
|
Calcium-Binding Proteins | 1 | 1999 | 1078 | 0.110 |
Why?
|
Down Syndrome | 1 | 2022 | 916 | 0.110 |
Why?
|
Vision Disorders | 1 | 2021 | 1090 | 0.110 |
Why?
|
Hypothalamus | 1 | 2018 | 1003 | 0.110 |
Why?
|
Malaria, Falciparum | 1 | 2001 | 1075 | 0.110 |
Why?
|
Nasal Cavity | 1 | 2015 | 310 | 0.100 |
Why?
|
Headache | 1 | 2021 | 1260 | 0.100 |
Why?
|
Nose Neoplasms | 1 | 2015 | 250 | 0.100 |
Why?
|
Interleukin-3 | 2 | 1996 | 425 | 0.100 |
Why?
|
Memory | 2 | 2019 | 2192 | 0.100 |
Why?
|
Pelvic Neoplasms | 1 | 2014 | 249 | 0.100 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 1012 | 0.100 |
Why?
|
Radiation Pneumonitis | 1 | 2013 | 99 | 0.100 |
Why?
|
Markov Chains | 1 | 2016 | 974 | 0.100 |
Why?
|
Thoracic Neoplasms | 1 | 2014 | 269 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2019 | 1097 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2019 | 14762 | 0.100 |
Why?
|
Incidence | 5 | 2022 | 21525 | 0.100 |
Why?
|
Dose-Response Relationship, Immunologic | 4 | 1999 | 361 | 0.100 |
Why?
|
Plasmodium falciparum | 1 | 2001 | 1739 | 0.090 |
Why?
|
Choice Behavior | 1 | 2017 | 846 | 0.090 |
Why?
|
Parents | 4 | 2019 | 3593 | 0.090 |
Why?
|
Uveal Neoplasms | 1 | 2014 | 344 | 0.090 |
Why?
|
Communicable Disease Control | 1 | 2017 | 857 | 0.090 |
Why?
|
Chorionic Gonadotropin | 1 | 2013 | 458 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2016 | 3552 | 0.090 |
Why?
|
Esophagus | 1 | 2017 | 1040 | 0.090 |
Why?
|
Memory Disorders | 1 | 2018 | 1193 | 0.090 |
Why?
|
Breast Diseases | 1 | 2014 | 441 | 0.090 |
Why?
|
Neoplasm Staging | 7 | 2017 | 11218 | 0.090 |
Why?
|
Medical Oncology | 1 | 2022 | 2340 | 0.090 |
Why?
|
Intestine, Small | 1 | 2017 | 1217 | 0.090 |
Why?
|
Catheterization | 1 | 2016 | 1429 | 0.090 |
Why?
|
Alopecia | 1 | 2014 | 416 | 0.090 |
Why?
|
Thyroid Gland | 1 | 2017 | 1170 | 0.090 |
Why?
|
Patient Preference | 1 | 2017 | 946 | 0.090 |
Why?
|
Attitude to Health | 1 | 2019 | 2021 | 0.080 |
Why?
|
Photography | 1 | 2013 | 536 | 0.080 |
Why?
|
Aged, 80 and over | 10 | 2024 | 59550 | 0.080 |
Why?
|
Canada | 4 | 2019 | 2126 | 0.080 |
Why?
|
Lymph Node Excision | 5 | 2015 | 1267 | 0.080 |
Why?
|
Recovery of Function | 2 | 2016 | 2976 | 0.080 |
Why?
|
Cervical Vertebrae | 1 | 2015 | 978 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2000 | 4349 | 0.080 |
Why?
|
Clinical Clerkship | 1 | 2015 | 569 | 0.080 |
Why?
|
Life Expectancy | 1 | 2016 | 1249 | 0.080 |
Why?
|
Executive Function | 1 | 2017 | 1396 | 0.080 |
Why?
|
Radiosurgery | 1 | 2018 | 1329 | 0.080 |
Why?
|
Optic Chiasm | 2 | 2022 | 91 | 0.080 |
Why?
|
Motivation | 1 | 2019 | 2020 | 0.080 |
Why?
|
Lung | 4 | 2018 | 10067 | 0.080 |
Why?
|
Ferrosoferric Oxide | 1 | 2009 | 349 | 0.080 |
Why?
|
SEER Program | 1 | 2013 | 1443 | 0.080 |
Why?
|
Mothers | 1 | 2019 | 2208 | 0.070 |
Why?
|
Sepsis | 1 | 2022 | 2604 | 0.070 |
Why?
|
Cerebellum | 1 | 2015 | 1520 | 0.070 |
Why?
|
Echocardiography | 2 | 2022 | 5037 | 0.070 |
Why?
|
Magnetite Nanoparticles | 1 | 2009 | 310 | 0.070 |
Why?
|
Neuropsychological Tests | 3 | 2018 | 7119 | 0.070 |
Why?
|
Creatine Kinase, MB Form | 1 | 2008 | 203 | 0.070 |
Why?
|
Skin | 3 | 2014 | 4499 | 0.070 |
Why?
|
Dextrans | 1 | 2009 | 574 | 0.070 |
Why?
|
Etoposide | 2 | 2022 | 638 | 0.070 |
Why?
|
Vacuum | 1 | 2007 | 65 | 0.070 |
Why?
|
Analysis of Variance | 4 | 2018 | 6214 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1367 | 0.070 |
Why?
|
Lymphedema | 1 | 2014 | 526 | 0.070 |
Why?
|
Biopsy | 1 | 2019 | 6779 | 0.070 |
Why?
|
Recurrence | 2 | 2023 | 8507 | 0.070 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2013 | 783 | 0.070 |
Why?
|
Body Height | 1 | 2013 | 1562 | 0.070 |
Why?
|
Axilla | 3 | 2015 | 622 | 0.070 |
Why?
|
4-Aminobenzoic Acid | 1 | 2006 | 23 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 1999 | 3601 | 0.070 |
Why?
|
Decision Support Systems, Clinical | 1 | 2016 | 1178 | 0.070 |
Why?
|
Receptor, erbB-2 | 2 | 2016 | 2597 | 0.070 |
Why?
|
Confidence Intervals | 3 | 2017 | 2921 | 0.070 |
Why?
|
Cause of Death | 2 | 2014 | 3716 | 0.060 |
Why?
|
Prone Position | 1 | 2007 | 203 | 0.060 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2015 | 3681 | 0.060 |
Why?
|
Thymus Neoplasms | 1 | 2008 | 272 | 0.060 |
Why?
|
Salvage Therapy | 1 | 2012 | 1274 | 0.060 |
Why?
|
International Agencies | 2 | 2017 | 244 | 0.060 |
Why?
|
Decision Making | 1 | 2019 | 3951 | 0.060 |
Why?
|
Collagen Type IV | 1 | 2005 | 125 | 0.060 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2011 | 934 | 0.060 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2006 | 348 | 0.060 |
Why?
|
Lymphoma | 1 | 2013 | 1900 | 0.060 |
Why?
|
Necrosis | 2 | 2019 | 1616 | 0.060 |
Why?
|
Heart Diseases | 1 | 1997 | 2817 | 0.060 |
Why?
|
Brachytherapy | 1 | 2011 | 1220 | 0.060 |
Why?
|
Immunization, Passive | 2 | 1996 | 618 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3230 | 0.050 |
Why?
|
Cells, Cultured | 4 | 2001 | 18984 | 0.050 |
Why?
|
Seizures | 1 | 2016 | 2996 | 0.050 |
Why?
|
Disease Progression | 5 | 2021 | 13640 | 0.050 |
Why?
|
Risk Factors | 8 | 2019 | 74881 | 0.050 |
Why?
|
Troponin T | 1 | 2008 | 786 | 0.050 |
Why?
|
Fat Necrosis | 2 | 2014 | 60 | 0.050 |
Why?
|
Peptide Fragments | 2 | 2022 | 5143 | 0.050 |
Why?
|
Melanocytes | 1 | 2006 | 508 | 0.050 |
Why?
|
Organ Size | 1 | 2008 | 2261 | 0.050 |
Why?
|
Survival Rate | 3 | 2013 | 12825 | 0.050 |
Why?
|
Circle of Willis | 1 | 2022 | 77 | 0.050 |
Why?
|
Neoadjuvant Therapy | 3 | 2022 | 2902 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8616 | 0.050 |
Why?
|
Palliative Care | 1 | 2017 | 3640 | 0.050 |
Why?
|
Students, Medical | 1 | 2015 | 1962 | 0.050 |
Why?
|
Enzyme Precursors | 1 | 2001 | 166 | 0.050 |
Why?
|
Glioblastoma | 1 | 2016 | 3458 | 0.050 |
Why?
|
T-Box Domain Proteins | 1 | 2024 | 471 | 0.050 |
Why?
|
Coronary Disease | 1 | 2016 | 5915 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7074 | 0.050 |
Why?
|
Risk | 1 | 2013 | 9602 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12985 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5514 | 0.050 |
Why?
|
Liver | 1 | 2017 | 7571 | 0.050 |
Why?
|
Phosphatidylinositol Phosphates | 1 | 2001 | 201 | 0.050 |
Why?
|
Patient Satisfaction | 3 | 2024 | 3485 | 0.050 |
Why?
|
Diarrhea | 2 | 2019 | 1317 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14652 | 0.040 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 8045 | 0.040 |
Why?
|
Cloning, Molecular | 2 | 1996 | 4168 | 0.040 |
Why?
|
Postoperative Period | 2 | 2016 | 1824 | 0.040 |
Why?
|
Visual Acuity | 3 | 2014 | 2714 | 0.040 |
Why?
|
Carcinoma | 1 | 2011 | 2324 | 0.040 |
Why?
|
Memory, Short-Term | 2 | 2017 | 1004 | 0.040 |
Why?
|
Computer Simulation | 1 | 2013 | 6259 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7871 | 0.040 |
Why?
|
Infant, Newborn | 3 | 2017 | 26389 | 0.040 |
Why?
|
Histamine | 1 | 2001 | 496 | 0.040 |
Why?
|
Caliciviridae Infections | 1 | 2019 | 29 | 0.040 |
Why?
|
Norovirus | 1 | 2019 | 37 | 0.040 |
Why?
|
Retinal Detachment | 2 | 2014 | 429 | 0.040 |
Why?
|
Virulence Factors, Bordetella | 1 | 1999 | 154 | 0.040 |
Why?
|
Culture Media | 1 | 2001 | 893 | 0.040 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2008 | 1750 | 0.040 |
Why?
|
Pertussis Toxin | 1 | 1999 | 176 | 0.040 |
Why?
|
Acetophenones | 1 | 1999 | 52 | 0.040 |
Why?
|
Chromosomes, Artificial, Yeast | 1 | 1999 | 113 | 0.040 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2001 | 393 | 0.040 |
Why?
|
Benzopyrans | 1 | 1999 | 63 | 0.040 |
Why?
|
Seroma | 1 | 2019 | 75 | 0.040 |
Why?
|
src-Family Kinases | 1 | 2001 | 539 | 0.040 |
Why?
|
Rett Syndrome | 1 | 2000 | 164 | 0.040 |
Why?
|
Hybrid Cells | 1 | 1999 | 421 | 0.040 |
Why?
|
Troponin | 1 | 2022 | 536 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2021 | 794 | 0.040 |
Why?
|
Orbit | 1 | 2022 | 459 | 0.040 |
Why?
|
Staurosporine | 1 | 1999 | 241 | 0.040 |
Why?
|
Tissue Expansion Devices | 1 | 2019 | 160 | 0.040 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2010 | 2184 | 0.040 |
Why?
|
Obesity | 2 | 1997 | 13090 | 0.040 |
Why?
|
Mammography | 1 | 2009 | 2429 | 0.040 |
Why?
|
Dehydration | 1 | 2019 | 216 | 0.040 |
Why?
|
Kinetics | 2 | 1996 | 6287 | 0.040 |
Why?
|
Drug Synergism | 2 | 2000 | 1756 | 0.040 |
Why?
|
Dendrites | 1 | 2000 | 471 | 0.040 |
Why?
|
Oculomotor Muscles | 1 | 2022 | 405 | 0.040 |
Why?
|
Esophageal Neoplasms | 1 | 2008 | 1660 | 0.040 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 492 | 0.040 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2000 | 661 | 0.040 |
Why?
|
Pneumonia | 1 | 2009 | 2159 | 0.040 |
Why?
|
Receptors, IgE | 1 | 1999 | 375 | 0.040 |
Why?
|
Carbazoles | 1 | 1999 | 230 | 0.040 |
Why?
|
Survival Analysis | 3 | 2016 | 10100 | 0.040 |
Why?
|
Extracellular Matrix | 1 | 2005 | 1730 | 0.030 |
Why?
|
Sensory Thresholds | 1 | 1998 | 377 | 0.030 |
Why?
|
United States | 5 | 2019 | 72951 | 0.030 |
Why?
|
Risk Assessment | 4 | 2022 | 24295 | 0.030 |
Why?
|
Probability | 1 | 2022 | 2476 | 0.030 |
Why?
|
Texas | 1 | 2018 | 410 | 0.030 |
Why?
|
Body Constitution | 1 | 1997 | 273 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 891 | 0.030 |
Why?
|
Ischemic Attack, Transient | 1 | 2022 | 874 | 0.030 |
Why?
|
Acute Disease | 2 | 2019 | 7241 | 0.030 |
Why?
|
Florida | 1 | 2018 | 417 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2018 | 300 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2019 | 15831 | 0.030 |
Why?
|
Polymerase Chain Reaction | 3 | 2006 | 6066 | 0.030 |
Why?
|
Melanins | 1 | 1998 | 291 | 0.030 |
Why?
|
Contrast Media | 1 | 2009 | 5329 | 0.030 |
Why?
|
Cardiotoxins | 1 | 2016 | 36 | 0.030 |
Why?
|
Mannose | 1 | 1996 | 121 | 0.030 |
Why?
|
Base Sequence | 2 | 1999 | 12415 | 0.030 |
Why?
|
Telephone | 1 | 2019 | 629 | 0.030 |
Why?
|
Logistic Models | 2 | 2022 | 13278 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 638 | 0.030 |
Why?
|
Rural Health | 1 | 1997 | 302 | 0.030 |
Why?
|
Calibration | 1 | 2018 | 814 | 0.030 |
Why?
|
Cerebrovascular Disorders | 1 | 2022 | 1479 | 0.030 |
Why?
|
Stroke Volume | 2 | 2022 | 5618 | 0.030 |
Why?
|
Sex Distribution | 2 | 1997 | 2274 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 1998 | 1751 | 0.030 |
Why?
|
Breast Implantation | 1 | 2018 | 225 | 0.030 |
Why?
|
Elastic Modulus | 1 | 2016 | 209 | 0.030 |
Why?
|
Cricetinae | 1 | 1999 | 2416 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 428 | 0.030 |
Why?
|
Chromatography, Ion Exchange | 1 | 1995 | 292 | 0.030 |
Why?
|
Radiation, Ionizing | 1 | 2015 | 251 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2000 | 1325 | 0.030 |
Why?
|
Topotecan | 1 | 2015 | 131 | 0.030 |
Why?
|
Intention | 1 | 2017 | 347 | 0.030 |
Why?
|
Urban Health | 1 | 1997 | 532 | 0.030 |
Why?
|
Cytokines | 1 | 1990 | 7438 | 0.030 |
Why?
|
Age Distribution | 2 | 1997 | 2869 | 0.030 |
Why?
|
Microbiological Techniques | 1 | 2015 | 97 | 0.030 |
Why?
|
Protein Kinase C | 1 | 1999 | 1206 | 0.030 |
Why?
|
DNA Primers | 1 | 1999 | 2826 | 0.030 |
Why?
|
Hematoma | 1 | 2019 | 766 | 0.030 |
Why?
|
Regression Analysis | 2 | 2015 | 6329 | 0.030 |
Why?
|
Career Mobility | 1 | 1996 | 262 | 0.030 |
Why?
|
Cell Line | 2 | 2000 | 15563 | 0.030 |
Why?
|
Telangiectasis | 1 | 2014 | 78 | 0.030 |
Why?
|
Animals | 8 | 2006 | 168930 | 0.030 |
Why?
|
Chromatography, Affinity | 1 | 1995 | 524 | 0.030 |
Why?
|
Anthracyclines | 1 | 2016 | 286 | 0.030 |
Why?
|
Prosthesis Failure | 1 | 2019 | 1208 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1733 | 0.030 |
Why?
|
Lymphocytes | 1 | 2001 | 2605 | 0.030 |
Why?
|
Chick Embryo | 2 | 2006 | 972 | 0.030 |
Why?
|
Mice | 6 | 2006 | 81889 | 0.030 |
Why?
|
Sex Factors | 3 | 2016 | 10619 | 0.030 |
Why?
|
International Cooperation | 1 | 2020 | 1434 | 0.030 |
Why?
|
Dietary Supplements | 1 | 2006 | 3429 | 0.030 |
Why?
|
Cicatrix | 1 | 2019 | 798 | 0.030 |
Why?
|
Uncertainty | 1 | 2018 | 764 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2024 | 20144 | 0.030 |
Why?
|
Educational Status | 2 | 1997 | 2510 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 4 | 2018 | 20708 | 0.030 |
Why?
|
DNA, Complementary | 1 | 1996 | 1989 | 0.030 |
Why?
|
Triage | 1 | 2019 | 995 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2001 | 2426 | 0.020 |
Why?
|
Prejudice | 1 | 1996 | 568 | 0.020 |
Why?
|
Erythrocytes | 1 | 2001 | 2412 | 0.020 |
Why?
|
Monocytes | 1 | 2001 | 2600 | 0.020 |
Why?
|
Skin Pigmentation | 1 | 2014 | 278 | 0.020 |
Why?
|
Species Specificity | 1 | 1996 | 2413 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2885 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 6104 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2018 | 1313 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1995 | 2746 | 0.020 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2011 | 43 | 0.020 |
Why?
|
Elasticity Imaging Techniques | 1 | 2016 | 398 | 0.020 |
Why?
|
Indoles | 1 | 1999 | 1834 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12534 | 0.020 |
Why?
|
Specimen Handling | 1 | 2015 | 706 | 0.020 |
Why?
|
Melanoma | 2 | 2006 | 5700 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 1999 | 4619 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2005 | 10745 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2019 | 1851 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2008 | 22248 | 0.020 |
Why?
|
Esthetics | 1 | 2011 | 328 | 0.020 |
Why?
|
Epitopes | 1 | 1996 | 2526 | 0.020 |
Why?
|
Body Mass Index | 3 | 2014 | 13050 | 0.020 |
Why?
|
Brain | 1 | 2016 | 27159 | 0.020 |
Why?
|
Comprehension | 1 | 2015 | 638 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2022 | 3935 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2016 | 1320 | 0.020 |
Why?
|
Walking | 1 | 2016 | 1201 | 0.020 |
Why?
|
N-Formylmethionine Leucyl-Phenylalanine | 1 | 1989 | 221 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2015 | 2234 | 0.020 |
Why?
|
Cisplatin | 1 | 2015 | 1655 | 0.020 |
Why?
|
Feces | 1 | 2015 | 1505 | 0.020 |
Why?
|
Femur Head | 1 | 2010 | 297 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1999 | 3721 | 0.020 |
Why?
|
Lung Neoplasms | 2 | 2014 | 13485 | 0.020 |
Why?
|
Doxorubicin | 1 | 2015 | 2229 | 0.020 |
Why?
|
Pelvic Bones | 1 | 2010 | 274 | 0.020 |
Why?
|
Faculty, Medical | 1 | 1996 | 1226 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2022 | 3531 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2010 | 11094 | 0.020 |
Why?
|
Hypersensitivity, Delayed | 1 | 1989 | 491 | 0.020 |
Why?
|
Social Support | 1 | 2017 | 2191 | 0.020 |
Why?
|
Glucocorticoids | 1 | 1997 | 2158 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3609 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2006 | 0.020 |
Why?
|
World Health Organization | 1 | 2013 | 1327 | 0.020 |
Why?
|
Calcium | 1 | 2000 | 5783 | 0.020 |
Why?
|
Antibodies | 1 | 1995 | 2421 | 0.020 |
Why?
|
Plant Proteins | 1 | 1989 | 375 | 0.020 |
Why?
|
Tamoxifen | 1 | 2011 | 967 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 1995 | 3738 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2001 | 12791 | 0.020 |
Why?
|
Temporal Lobe | 1 | 2014 | 1716 | 0.020 |
Why?
|
Qualitative Research | 1 | 2017 | 3138 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1326 | 0.020 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 1989 | 546 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 1996 | 2783 | 0.020 |
Why?
|
Interleukin-1 | 1 | 1989 | 1251 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12064 | 0.020 |
Why?
|
Cost of Illness | 1 | 2015 | 1949 | 0.020 |
Why?
|
Dermatitis, Atopic | 1 | 1993 | 734 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 376 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2006 | 22352 | 0.020 |
Why?
|
Health Expenditures | 1 | 2017 | 2390 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2017 | 3832 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2014 | 26310 | 0.010 |
Why?
|
Fibrosis | 1 | 2011 | 2077 | 0.010 |
Why?
|
Urinary Bladder | 1 | 2010 | 1155 | 0.010 |
Why?
|
Adjuvants, Immunologic | 1 | 1989 | 996 | 0.010 |
Why?
|
Desensitization, Immunologic | 1 | 1989 | 546 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1995 | 13411 | 0.010 |
Why?
|
Retina | 1 | 2014 | 2660 | 0.010 |
Why?
|
Prevalence | 2 | 1997 | 15835 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2011 | 1536 | 0.010 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2008 | 454 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 4056 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1989 | 1560 | 0.010 |
Why?
|
Rats | 1 | 1999 | 23717 | 0.010 |
Why?
|
Observer Variation | 1 | 2009 | 2614 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 1995 | 17608 | 0.010 |
Why?
|
Registries | 1 | 2019 | 8351 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10384 | 0.010 |
Why?
|
Allergens | 1 | 1989 | 1436 | 0.010 |
Why?
|
Leukocytes | 1 | 1990 | 2035 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 1997 | 9244 | 0.010 |
Why?
|
Curriculum | 1 | 2015 | 3783 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2005 | 2012 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2019 | 5368 | 0.010 |
Why?
|
Hypersensitivity | 1 | 1990 | 1169 | 0.010 |
Why?
|
Macrophages | 1 | 1995 | 5783 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5992 | 0.010 |
Why?
|
Apoptosis | 2 | 2006 | 9513 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2005 | 11061 | 0.010 |
Why?
|
Cell Line, Tumor | 2 | 2006 | 17088 | 0.010 |
Why?
|
Blotting, Western | 1 | 2006 | 5022 | 0.010 |
Why?
|
Mice, Nude | 1 | 2005 | 3616 | 0.010 |
Why?
|
Signal Transduction | 1 | 2001 | 23619 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2005 | 3093 | 0.010 |
Why?
|
Neurofilament Proteins | 1 | 2000 | 335 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2005 | 3757 | 0.010 |
Why?
|
Ligands | 1 | 2005 | 3275 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2005 | 2629 | 0.010 |
Why?
|
Cell Communication | 1 | 2005 | 1660 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15908 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2006 | 6222 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 30237 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2000 | 2275 | 0.010 |
Why?
|
Algorithms | 1 | 2016 | 14072 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15416 | 0.010 |
Why?
|
Microtubule-Associated Proteins | 1 | 2000 | 1071 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2006 | 10445 | 0.010 |
Why?
|
Poaceae | 1 | 1989 | 25 | 0.010 |
Why?
|
Phosphorylation | 1 | 2000 | 8307 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5387 | 0.010 |
Why?
|
Pollen | 1 | 1989 | 80 | 0.010 |
Why?
|
Antigens, Plant | 1 | 1989 | 104 | 0.010 |
Why?
|
Prostaglandin D2 | 1 | 1989 | 109 | 0.000 |
Why?
|
Income | 1 | 1997 | 1875 | 0.000 |
Why?
|
Skin Neoplasms | 1 | 2005 | 5861 | 0.000 |
Why?
|
Nose | 1 | 1989 | 522 | 0.000 |
Why?
|
Aging | 1 | 2000 | 8731 | 0.000 |
Why?
|
Adrenal Cortex Hormones | 1 | 1989 | 1885 | 0.000 |
Why?
|